Company ProfilePremium

SinoMab BioScience Limited

Company Profile Analysis

中國抗體製藥有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
SinoMab BioScience Limited - Company showcase

Year Founded & Workforce

2001

42 Employees

SinoMab BioScience Limited logo

SinoMab BioScience Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

SinoMab BioScience Limited Overview

SinoMab is the first Hong Kong-based biotechnology company listed under HKEX Chapter 18A. It is a clinical-stage, pre-revenue developer of first-in-class and potential best-in-class therapeutic antibodies for autoimmune, inflammatory and other debilitating diseases. After 25 years built around the anti-CD22 antibody Suciraslimab (SM03), the company withdrew Suciraslimab's rheumatoid arthritis BLA in July 2025. It has since re-centred on SM17, a global first-in-class anti-IL-25 receptor (IL-17RB) antibody now in a ~210-patient Phase 2 atopic dermatitis trial in China, with IBD as a second indication. Earlier assets are an anti-γc (CD132) antibody, hC2, for alopecia areata and vitiligo, and a RANKL × sclerostin bispecific for osteoporosis. In 2026 the company pivoted to an "asset-light, high-efficiency" model: it exited the Haikou plant lease and agreed to sell the Suzhou campus for RMB280 m. Value realisation now depends on out-licensing. The company also holds residual economics in the BTK inhibitor SN1011, which was sublicensed by Everest Medicines to Travere Therapeutics in June 2026.


Company's own description (Interim Results 2026, Annual Report 2025). The company describes itself as a Hong Kong-based biopharmaceutical company dedicated to discovering, researching and developing innovative therapeutic antibody drugs. Its focus is autoimmune, inflammatory and other debilitating diseases with significant unmet need, using novel targets and novel mechanisms of action. Its stated R&D philosophy is "differentiated innovation" toward First-in-Class (FIC) and Best-in-Class (BIC) antibodies. Its stated operating model since 1H 2026 is "asset-light, high-efficiency": internal resources go to discovery, translational science and clinical development, while CMC and GMP manufacturing are outsourced to CDMOs and studies to CROs. The Annual Report 2025 still described "integration of our Hong Kong-based innovative R&D team and PRC-based manufacturing capabilities". The interim language marks the formal abandonment of in-house commercial-scale manufacturing. The stated vision is "to become a global leader in the development of innovative therapeutics for immunological and other debilitating diseases".

Business model. SinoMab has no product revenue. Its income statement opens with "other income and gains" (bank interest, fair-value gains on wealth-management products, government grants, FX gains), which totalled RMB29.3 m in FY2025 and RMB23.5 m in 1H 2026. Expenses are R&D costs and administrative costs. The intended monetisation is out-licensing and partnering (regional or global licences, co-development) of clinical-stage assets. Management called this "the Company's core strategy" in the 2025 Chairman's Statement. Earlier plans for self-commercialisation are now subordinate. Those plans included a marketing team built for Suciraslimab in RA and a commercial-scale Suzhou plant. The only existing licensing economics are with Everest Medicines on SN1011: single-digit percentages of downstream upfronts, double-digit percentages of non-renal milestones and single-digit percentages of renal milestones, per the 7 April 2026 licence.

Revenue-model mix (FY2025). Product 0%; service 0%; subscription 0%; licensing 0% recognised as revenue. Licensing is the prospective model.

Value-chain position. The company has historically been vertically integrated: target discovery → antibody engineering (proprietary "framework-patching" humanisation) → preclinical → clinical → CMC/GMP → planned commercialisation. From 2026 it is repositioning to the discovery and early/mid-clinical development end of the chain, with manufacturing outsourced and late-stage development and commercialisation expected to sit with licensees.

Customer types (prospective). Global and Chinese pharmaceutical companies as licensees or partners. Ultimately, patients and prescribers in dermatology, gastroenterology, rheumatology, respiratory medicine and bone health.

End-markets. Atopic dermatitis (AD), inflammatory bowel disease (Crohn's disease and ulcerative colitis), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), idiopathic pulmonary fibrosis (IPF), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, alopecia areata (AA), vitiligo, osteoporosis, non-Hodgkin's lymphoma (SM09), and Alzheimer's disease or MCI as an exploratory CNS application of Suciraslimab.

Independent characterisation. SinoMab is best understood as a sub-scale, single-modality antibody discovery house. It is now a one-key-asset story (SM17) with a two-asset preclinical option set (hC2, RANKL×SOST bsAb) and a royalty-like residual on SN1011. The 2025 decision to drop the RA BLA after communications with CDE wrote off the company's historic flagship thesis. That thesis was eight years of public positioning of SM03 as the first anti-CD22 mAb for RA. The 2026 asset sales convert stranded manufacturing capex into runway. The equity is now effectively a binary-weighted option on (i) SM17 Phase 2 AD data, guided for 1Q 2027, and (ii) management's ability to strike an ex-China licence.

Strategy

Stated strategic themes (Interim 2026; AR 2025 Chairman's Statement), paraphrased by theme:

  1. Differentiated innovation: focus on FIC/BIC antibodies against novel pathways (alarmins, γc, non-depleting CD22, multispecifics).

  2. Asset-light, high-efficiency operating model: exit fixed manufacturing (Haikou lease terminated; Suzhou being sold); use CROs and CDMOs for process development, pilot-scale, GMP and clinical supply.

  3. Out-licensing as core strategy: global and regional licences, co-development, technology licensing, with emphasis on SM17, hC2 and multispecific programmes. Management attended JPM Healthcare Conference (Jan 2026), LifeArc Translational Science Summit and BIO 2026.

  4. Indication expansion of SM17: "pipeline-in-a-drug" across AD → IBD → asthma, IPF and CRSwNP.

  5. Multispecific build-out: use validated targets as building blocks for bispecifics and multispecifics, led by the osteoporosis bsAb.

  6. Capability partnerships: SYSU-IAS joint lab; exploring AI for target identification (AR 2025).

Initiatives in the last 24 months.

No quantified targets were identified.

Cost programmes: FY2025 R&D team optimisation (employment costs −RMB9.5 m) and admin staff optimisation (−RMB16.4 m). No formal savings target was published.

Medium-term financial targets or guidance: none published. The company gives only pipeline timelines (above) and a use-of-proceeds schedule running to end-2027 or 2028.

Products & Services

All products sit in the single R&D segment. None is marketed. Pricing models are not applicable or not publicly disclosed.

SM17 — anti-IL-25 receptor (IL-17RB) mAb (key product)

Description: Global first-in-class humanised IgG4-κ mAb blocking the receptor of the alarmin IL-25 on ILC2s and Th2 cells. It suppresses downstream IL-4, IL-5, IL-9 and IL-13. Preclinical data also show Th17 inhibition and anti-fibrotic activity (Interim 2026).

Origin: The company states it has been "entrusted by LifeArc" (UK medical research charity) to develop and commercialise SM17 in all fields worldwide. LifeArc's precise economic interest (royalties or milestones) is not publicly disclosed.

Clinical status: - US Phase 1 in healthy volunteers (77 subjects) completed 2023.

  • China Phase 1a bridging completed May 2024.

  • China Phase 1b in AD (32 patients) positive April 2025. High dose (600 mg per media reports): NRS-4 itch response 91.7%, EASI-75 75%, IGA 0/1 41.7%.

  • Subcutaneous bridging study (30 healthy subjects) positive topline 25 March 2026: one Grade 1 injection-site rash and no ≥Grade 3 drug-related TEAE or SAE.

  • Phase 2 AD (NCT07445919, SM17-201): randomised, double-blind, placebo-controlled, dose-finding, five arms (1:1:1:1:1), ~210 patients in China, SC formulation. First patient dosed 31 March 2026; 86 enrolled by 30 June 2026. Enrolment completion targeted 3Q 2026; topline guided 1Q 2027. ClinicalTrials.gov lists estimated primary completion as 25 April 2027.

  • Second Phase 2 in AD being prepared in Australia.

  • IBD (CD and UC) IND approved by NMPA on 24 February 2026; Phase 2a in UC under evaluation.

  • IPF IND (US and China) planned per the Annual Report 2025.

Target customers: Dermatologists (moderate-to-severe AD) and gastroenterologists (IBD); potentially pulmonologists (asthma, IPF, CRSwNP).

Key differentiation claim: Faster and deeper itch relief than IL-4/IL-13 agents, with safety superior to JAK inhibitors. This is the company's claim based on cross-trial comparison, which is a methodological caveat. "Pipeline-in-a-drug" positioning.

Suciraslimab (SM03) — anti-CD22 mAb (former flagship)

Description: Potential global first-in-class, non-depleting anti-CD22 mAb. The company's positioning: "B-cell modulation without depletion", "dual mechanism and dual regulation", and "organ protection" (preclinical proteinuria reduction in a lupus model).

Status: RA Phase 3 met its primary endpoint in April 2023: ACR20 ≈50% at week 24, rising to >65% at week 52 and >70% through week 104 of extension. BLA accepted September 2023, then voluntarily withdrawn 14 July 2025 after CDE communications. Media citing the company reported the need for supplementary early-stage efficacy data.

Now: SLE Phase 2 proof-of-concept in China "remains under evaluation as part of longer-term plans" (Interim 2026). This is a softer stance than the "advance at full speed" language of July 2025. IND enablement for Alzheimer's disease is planned.

Publications: Journal of Neuroinflammation (Feb 2025); Journal of Translational Autoimmunity (Jun 2026).

IP: 4 PRC and 4 US invention patents (US patents also cover SM06), plus 1 South Africa patent.

Anti-CGC antibody (hC2) — anti-common-gamma-chain (CD132/γc) mAb

Description: In-house first-in-class humanised anti-γc antibody that modulates signalling of IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. It partially preserves IL-2 signalling (~50%), which the company says helps maintain Treg function, and it avoids the TEC-kinase off-target effects of JAK inhibitors.

Data: Journal of Immunology (Mar 2025); SID Annual Meeting 2026 (Chicago, May 2026); Journal of Investigative Dermatology (Jun 2026). Humanised AA model hair-loss reversal p<0.001; vitiligo depigmentation reduction p<0.05.

Status: CMC optimisation and IND-enabling toxicology. IND for AA to FDA and NMPA simultaneously targeted 4Q 2026. First-in-human study end-2026 or early 2027; New Zealand and Australia considered as sites. Vitiligo is the follow-on indication.

Bispecific antibody (bsAb) — RANKL × sclerostin

Description: First-in-class bispecific designed to both promote bone formation (anti-SOST) and inhibit resorption (anti-RANKL). In-house studies show superior bone mineral density and microarchitecture versus denosumab and romosozumab (company claim).

Status: CMC optimisation and NHP toxicology; IND targeted 1H 2027. The company also cites FDA's December 2025 recognition of BMD as a clinical endpoint as an accelerator.

SM06 — second-generation humanised anti-CD22

  • Humanised via proprietary framework-patching; in vitro data suggest enhanced immunomodulation and half-life versus SM03. IND-enabling and CMC optimisation. PCT filed 2025.

SM09 — framework-patched humanised anti-CD20

  • Targets an epitope distinct from rituximab, obinutuzumab and ofatumumab. Indications: NHL and autoimmune diseases. IND-enabling stage I. IP: 2 PRC and 3 US patents, plus one each in the EU, India, Singapore and Japan.

SN1011 (EVER001 / civorebrutinib) — third-generation covalent reversible BTK inhibitor (out-licensed)

Status: - Four NMPA INDs (SLE 2020; pemphigus 2021; MS 2022; NMOSD 2022).

  • Renal rights licensed to Everest Medicines in 2021; remaining global rights licensed 7 April 2026.

  • Everest reported positive Phase 1b/2a primary membranous nephropathy data (ERA 2025).

  • Everest–Travere licence (2 June 2026): US$112.5 m upfront, up to US$1.03 bn milestones across up to five indications, tiered high-single- to double-digit royalties to Everest.

SinoMab economics: Single-digit % of downstream upfronts; double-digit % of non-renal milestones; single-digit % of renal milestones. The cash amount SinoMab receives from the Travere upfront is not publicly disclosed. Arithmetic bound for illustration only: a single-digit share of US$112.5 m implies ~US$1–10 m. Whether co-licensor Evopoint shares in this is not disclosed.

Disclosed but undescribed candidates

SM18: (PCT national phase 2025; IND-enabling) and SM32 (IND-enabling to commence). Both are funded from the July 2025 placing proceeds per the revised use-of-proceeds table (Interim 2026). Targets not publicly disclosed.

  • At least two further unnamed candidates (patents not yet filed), each allocated ~HK$25 m.

  • An "SM17-derived bsAb" appears on the 2026 pipeline chart; details not disclosed.

Services

  • None offered commercially. The SYSU-IAS joint laboratory is for internal R&D.

Financial Narrative

Income statement (five-year summary)

Source: Annual Report 2025, Financial Summary (audited). Income tax is nil in all years. Operating income, EBITDA and margins are not meaningful with zero revenue; EBITDA is not disclosed. Revenue CAGR is NM. Net-loss CAGR FY2021–25 is −22.3% (derived); R&D CAGR is −20.0% (derived). The R&D % of net-loss row is derived.

FY2024–FY2025 detail (from AR 2025 MD&A)

FY2024 other income is derived from the disclosed RMB21.7 m increase; FY2024 other expenses are derived from the disclosed RMB21.5 m decrease. FY2024 other expenses included a one-off RMB12.6 m loss on terminating a purchase contract and a RMB9.5 m FX loss.

Commentary. The five-year trajectory is one of deliberate contraction:

FY2021–22 peak spend: Losses of ~RMB285–288 m a year funded SM03 Phase 3, SN1011 multi-indication INDs and SM17 US Phase 1, against IPO cash of HK$1.27 bn.

FY2023–24: R&D fell 25% and 30% respectively as SM03 moved to BLA review and lab spend dropped. FY2024 still carried heavy admin costs (RMB67.7 m), including pre-commercial infrastructure for an RA launch that never happened.

FY2025 inflection: The loss fell 43.3% to RMB105.0 m. Drivers were R&D headcount optimisation (employment costs −RMB9.5 m), admin staff optimisation (−RMB16.4 m), and a RMB21.7 m rise in other income (FX gain +RMB11.4 m, lease-termination gain +RMB7.4 m, grants +RMB4.1 m). Roughly half of the FY2025 improvement is therefore non-operational or one-off.

1H 2026 re-acceleration: Spending rose again as SM17 entered Phase 2 (below).

Interim comparison

Source: Interim Results 2026. Net loss ex-impairment as disclosed by the company.

Commentary. The 1H 2026 underlying loss rose 43% year on year:

  • Phase 2 lab and experiment costs nearly doubled, from RMB13.7 m to RMB28.8 m.

  • Non-cash share-based payments rose (admin +RMB8.2 m; R&D employment +RMB5.2 m), from option and award grants in July 2025, March 2026 and June 2026.

  • Admin depreciation rose RMB7.4 m.

  • Operating cash burn stayed flat at ~RMB30 m, so much of the P&L increase is non-cash.

  • The RMB12.2 m FX gain flatters "other income" again.

Balance sheet

Source: AR 2025 Financial Summary. Totals and working capital are derived. Goodwill is nil. Intangible assets were RMB0.35 m at 31 Dec 2025 and RMB0.17 m at 30 Jun 2026 (Interim 2026).

Net debt is derived as borrowings minus cash; gearing is as reported (borrowings less cash, divided by equity).

30 June 2026 position (Interim 2026):

  • Cash RMB151.8 m; WMPs RMB22.9 m; pledged and restricted deposits RMB21.8 m; total funding RMB196.5 m.

  • Borrowings RMB260.2 m: current RMB114.4 m, non-current RMB145.8 m. Secured RMB146.2 m, unsecured RMB114.1 m. All RMB-denominated at 2.50–3.90%.

  • Maturity: RMB114.4 m within 1 year, RMB107.0 m in year 2, RMB38.8 m in years 3–5.

  • Unutilised facilities RMB311.9 m.

  • Net debt RMB108.4 m (derived); gearing 30.0%.

  • Total equity RMB361.5 m; net current assets RMB62.1 m.

  • Land, buildings and PPE carrying RMB336.3 m are mortgaged; pledged deposit RMB11.9 m.

Cash flow

The January 2024 placing raised HK$73.2 m net. FY2025 FCF is derived.

In 1H 2026, OCF was −RMB29.9 m, capex RMB20.5 m and net bank repayment RMB65.6 m; cash and equivalents fell RMB141.8 m before FX.

Ratios

All derived from the AR 2025 Financial Summary. FY2021 current ratio was 6.06x and liabilities/equity 0.53x. Bank debt/equity was 2.17x at FY2024, 0.64x at FY2025 and 0.72x at 30 June 2026. ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful (negative EBIT and EBITDA, no revenue, no inventory or receivables cycle).

Interpretation. Balance-sheet stress peaked at end-2024: negative working capital, current ratio 0.91x, gearing 185%, and only RMB61.9 m of cash against RMB419 m of debt. The 2025 placings (HK$493.7 m gross across May and August) were therefore a rescue-grade recapitalisation, not opportunistic. They lifted equity 2.6x and cut net debt to near zero.

Cash has since been re-consumed: down RMB155 m in six months, with RMB65.6 m of it spent on debt reduction. The Suzhou sale (RMB280 m) is now the swing factor. Secured borrowings of RMB146.2 m appear to be secured on the Suzhou property, with a maximum mortgage amount of RMB158.4 m. If these are repaid from proceeds, net cash uplift may be roughly RMB120–135 m (analyst estimate, not company guidance). Against an underlying cash burn of roughly RMB60–100 m a year, that implies runway into 2028 absent partnering income, subject to the SM17 Phase 2 cost profile.

Capital raising history (dilution)

Shares outstanding rose from about 1,091.7 m before the May 2025 placing (derived from the 49.17% public-float disclosure) to 1,386.6 m: +27% dilution in 2025 alone.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

MetricFY2023FY2024FY2025

Segment revenue – R&D of pharmaceutical products (CNY Mn)

000

Segment loss before tax (CNY Mn)

-243.1-185.1-105.0

Segment R&D costs (CNY Mn)

135.494.881.6

Contribution to group revenue (%)

000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Entities

EntityLocationRoleStatus (Oct 2026)Source

SinoMab BioScience Limited (listco)

Hong Kong Science Park

HQ, discovery R&D, management

Active

AR 2025

SinoMab BioScience (Shenzhen) Limited (深圳賽樂敏生物科技)

Shenzhen

Holding / operating; parent of Haikou entity

Active

HKEX 12 Mar 2026; etnet

SinoMab Biopharmaceutical (Haikou) Limited (formerly Hainan SinoMab Biotech)

Haikou, Hainan

Former production base (leased)

Lease terminated 12 Mar 2026

HKEX 12 Mar 2026

MediNexus Pharma (Suzhou) Limited (杏聯藥業(蘇州))

Suzhou Industrial Park

Owner of Suzhou campus

Vendor in RMB280 m disposal

Interim 2026

SinoMab Pty

Australia

Clinical-trial vehicle (SN1011 Phase 1; planned SM17/hC2 trials)

Not publicly detailed

etnet

Key Financials and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CNY Mn)

00000

Gross profit (CNY Mn)

00000

R&D costs (CNY Mn)

199.1180.4135.494.881.6

Loss before tax (CNY Mn)

-288.2-284.2-243.1-185.1-105.0

Net loss (CNY Mn)

-288.2-284.2-243.1-185.1-105.0

EPS basic and diluted (MYR Bn)

-0.29-0.29-0.24-0.17-0.09

Dividends per share (MYR Bn)

00000

R&D as % of net loss

69.163.555.751.277.7

Income Statement

MetricFY2024FY2025

Other income and gains (CNY Mn)

7.629.3

R&D – lab consumables and experiment costs (CNY Mn)

42.340.9

R&D – employment costs (CNY Mn)

32.523.0

R&D – others (CNY Mn)

19.917.8

Administrative expenses (CNY Mn)

67.746.4

Other expenses (CNY Mn)

22.20.7

Cash Flow and Per-Share Data

Metric1H20251H2026

Other income and gains (CNY Mn)

9.823.5

R&D costs (CNY Mn)

32.750.3

Administrative expenses (CNY Mn)

23.739.0

Finance costs (CNY Mn)

3.03.3

Impairment of non-current assets (CNY Mn)

056.3

Other expenses (CNY Mn)

0.21.8

Net loss (CNY Mn)

-49.8-127.4

Net loss ex-impairment (CNY Mn)

-49.8-71.1

EPS basic and diluted (MYR Bn)

-0.05-0.09

Net cash used in operating activities (CNY Mn)

-26.9-29.9

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Non-current assets (CNY Mn)

446.0561.3577.6567.8518.2

Current assets (CNY Mn)

595.7447.1270.2185.3389.9

Total assets (CNY Mn)

1,041.71,008.3847.8753.1908.1

Current liabilities (CNY Mn)

98.4187.4172.6203.5204.0

Non-current liabilities (CNY Mn)

263.1311.4379.6356.7196.2

Total liabilities (CNY Mn)

361.4498.8552.2560.2400.2

Total equity (CNY Mn)

680.2509.6295.6192.9507.9

Working capital (CNY Mn)

497.3259.797.5-18.2185.9

Key Financials

MetricFY2023FY2024FY2025

Cash and cash equivalents (CNY Mn)

203.761.9322.7

Total funding available incl. WMPs and pledged deposits (CNY Mn)

0141.4351.5

Balance Sheet and Margin Analysis (%)

MetricFY2024FY2025

Interest-bearing bank borrowings – total (CNY Mn)

419.3326.8

Short-term borrowings (CNY Mn)

0134.7

Long-term borrowings (CNY Mn)

0192.1

Net debt (CNY Mn)

357.44.1

Gearing ratio, company definition (%)

185.30.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY2024FY2025

Net cash used in operating activities (CNY Mn)

-130.8-70.5

Net cash from/(used in) investing activities (CNY Mn)

-94.516.3

Net cash from financing activities (CNY Mn)

73.3329.4

Capital expenditure (CNY Mn)

025.3

Free cash flow, OCF minus capex (CNY Mn)

0-95.8

Net proceeds from share issues (CNY Mn)

0428.1

Dividends paid (CNY Mn)

00

Share buybacks (CNY Mn)

00

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025

ROE on average equity (%)

-47.8-60.4-75.8-30.0

ROA on average total assets (%)

-27.7-26.2-23.1-12.6

Current ratio (x)

2.391.560.911.91

Total liabilities / equity (x)

0.981.872.900.79

Share Price & Returns

DateShares issuedPrice (HKD)Net proceeds (HKD Mn)Source

Nov 2019 (IPO)

~182.1 m + over-allotment

7.601,272.8

HKEX 14 Aug 2020

Jan 2024

56,834,7191.2973.2

Interim 2026

May 2025

112,810,8171.10124.0

Interim 2026

Aug 2025

182,072,4002.03369.5

AR 2025

Geographic Revenue

MetricFY2023FY2024FY2025

Revenue – Hong Kong (CNY Mn)

000

Revenue – Mainland China (CNY Mn)

000

Revenue – Rest of world (CNY Mn)

000

Share Price History

DatePrice (HKD)ContextSource

12 Nov 2019

7.60

IPO price

etnet

26 May 2020

3.50

Private block sale price (Forbest → Grogene)

HKEX

Jan 2024

1.29

Placing price

Interim 2026

May 2025

1.10

Placing price

AR 2025

16 Jul 2025

2.42

Intraday after RA BLA withdrawal

Tiger Brokers

Jul–Aug 2025

2.03

Placing price

AR 2025

~3 Sep 2025

2.70

Intraday after 1H 2025 results

Tiger Brokers

24 Dec 2025

1.48

Last quote on etnet snapshot

etnet

25 Feb 2026

2.10

Intraday after IBD IND

Tiger Brokers

~11 Jun 2026

1.36

After a ~26% late-session spike

Tiger Brokers

9 Jul 2026

1.13

Close, after Suzhou disposal

Investing.com

24 Jul 2026

1.20

Close (latest verified)

Investing.com

Valuation Snapshot

MultipleValueComment

Market cap

≈HK$1.66 bn (≈RMB1.51 bn)

1,386.6 m shares

P/B

≈4.2x

Equity RMB361.5 m (30 Jun 2026). GuruFocus showed P/TBV 5.06x at HK$1.57

EV

≈RMB1.58 bn

Market cap + debt RMB260.2 m − funding RMB196.5 m

EV after Suzhou proceeds (pro forma, analyst estimate)

≈RMB1.30 bn

If RMB280 m received

Balance Sheet (FY2025–1H2026)

MetricFY20251H2026

Due within 1 year (CNY Mn)

134.7114.4

Due in year 2 (CNY Mn)

92.6107.0

Due in years 3–5 (CNY Mn)

99.538.8

Total borrowings (CNY Mn)

326.8260.2

Analyst Conclusions

Management guidance (timelines only; no financial guidance):

  • SM17 Phase 2 AD enrolment complete in 3Q 2026; topline 1Q 2027.

  • Australian SM17 Phase 2 in preparation.

  • IBD: Phase 2a in UC under evaluation.

  • hC2: AA IND to FDA and NMPA in 4Q 2026; first-in-human end-2026 or early 2027.

  • RANKL×SOST bsAb IND in 1H 2027.

  • Suciraslimab SLE Phase 2 under evaluation; Alzheimer's IND enablement.

  • Use-of-proceeds schedule runs through end-2027 and 2028.

Consensus growth expectations: none available (no sell-side coverage identified).

Bull case

  1. SM17 replicates Phase 1b in Phase 2. A ~210-patient randomised dataset showing itch and skin efficacy differentiated from IL-4Rα agents, with clean safety, would make SM17 one of few clinically validated IL-25 pathway assets. That would be licensable into a market management sizes at US$27.7 bn globally by 2030.

  2. The asset-light pivot plus the Suzhou sale funds the company to the readout. RMB196.5 m of funding plus RMB280 m of gross disposal proceeds, against ~RMB30 m of half-year operating cash burn, removes near-term financing risk through 1Q 2027.

  3. Multiple shots on goal in 2026–27. hC2 IND, bsAb IND, IBD Phase 2a and SN1011 milestones via Travere give three to four additional catalysts in a strong China out-licensing environment (157 deals worth US$135.7 bn in 2025).

Bear case

  1. Phase 1b over-promise risk. Only 32 patients, single-country, cross-trial comparisons. The alarmin class has historically produced mixed results in AD, and IL-25 is the least-validated alarmin.

  2. Track record of strategic reversals and value destruction. The flagship RA BLA was withdrawn after eight years. The SLE pivot has been softened. Manufacturing assets were built and then sold at an impairment. Cumulative losses since FY2021 total RMB1.1 bn against a ~RMB1.5 bn market cap.

  3. Structural dilution and governance. Shares rose 27% in 2025; the 20% mandate is renewed; option grants are ongoing. The combined Chair/CEO/CSO role and a pledged 11.46% major holding create overhang. Absent a licence, a further placing before or after the readout is likely.

Key catalysts and monitorables (next 12 months)

  1. EGM result and completion of the Suzhou disposal; repayment of secured debt; net cash received.

  2. Announcement of completion of SM17 Phase 2 enrolment (~210 patients).

  3. SM17 Phase 2 AD topline (guided 1Q 2027).

  4. hC2 IND submissions (FDA and NMPA) in 4Q 2026.

  5. Any SM17 out-licensing term sheet (upfront size, territory split).

  6. SN1011 cash receipts from the Everest/Travere arrangement; Travere development milestones.

  7. FY2026 annual results (~March 2027): cash runway, impairment completeness, any going-concern language.

  8. New equity issuance under the 20% mandate.

  9. IBD Phase 2a initiation decision; Australian SM17 Phase 2 initiation.

  10. Board stability, Hainan Haiyao pledge status, and changes in substantial holdings.

Concluding analyst verdict

SinoMab enters late 2026 as a fundamentally different company from the one that listed in 2019. The integrated "discover-develop-manufacture-commercialise" model built around Suciraslimab for rheumatoid arthritis has been dismantled. The BLA was withdrawn in July 2025, the Haikou plant was exited in March 2026, and the Suzhou campus was agreed for sale at an RMB56 m loss in July 2026. What remains is a lean, Hong Kong-centred antibody discovery group with one mid-stage asset of genuine interest (SM17), two preclinical options with credible scientific rationale (hC2 and the RANKL×SOST bispecific), and a small residual interest in a BTK inhibitor now partnered at Nasdaq-company scale.

The financial record is poor by any absolute measure: zero revenue, RMB1.1 bn of losses over five years, and serial dilutive placings at prices far below the HK$7.60 IPO. But the trajectory since 2024 shows discipline. The FY2025 loss fell 43%, the balance sheet was repaired, and capital is now concentrated on SM17. The Phase 2 trial is enrolling ahead of plan and is formulated subcutaneously, the commercially relevant route.

The investment case is therefore binary and time-boxed. At roughly HK$1.7 bn of market value and about RMB1.3 bn of pro forma enterprise value after the Suzhou proceeds, the market is ascribing modest but non-trivial option value to SM17. A clean, differentiated Phase 2 readout in 1Q 2027 that converts into an ex-China licence could plausibly re-rate the equity, given prevailing China-to-global deal economics. A miss would leave a cash shell with preclinical assets and further dilution ahead.

We would characterise SinoMab as a high-risk, catalyst-driven speculative holding. The dominant monitorable is SM17 Phase 2 data quality, followed by disposal completion and any partnering announcement. Governance concentration and the company's record of strategic reversals warrant a persistent risk discount until execution is proven.


Appendix — Principal sources

  • SinoMab BioScience Limited, Interim Results Announcement for the six months ended 30 June 2026 (HKEX, 31 Aug 2026): https://www.hkexnews.hk/listedco/listconews/sehk/2026/0831/2026083102817.pdf

  • SinoMab BioScience Limited, Annual Report 2025 (HKEX, 27 Apr 2026): https://www.hkexnews.hk/listedco/listconews/sehk/2026/0427/2026042701477.pdf

  • HKEX announcements: delay in despatch of circular (27 Jul 2026; 10 Aug 2026); completion of subscriptions (29 May 2025; 29 Aug 2025; 12 & 31 Jan 2024; 16 Nov 2022); supplemental announcement on IPO proceeds (14 Aug 2020); FY2024 annual results (31 Mar 2025); Haikou lease termination (12 Mar 2026); SM17 Phase 2 first-patient-dosed (1 Apr 2026)

  • ClinicalTrials.gov NCT07445919 (SM17-201)

  • CICC (12 Nov 2019); Paul Hastings (12 Nov 2019); Herbert Smith Freehills; HKSTP (30 Dec 2019); ACN Newswire releases (2019–2026)

  • etnet (shareholders, listing price, subsidiaries); Investing.com (prices, market cap, employees); GuruFocus (ISIN, valuation snapshot); financialfilings.com (filing index, LEI); PitchBook profile

  • Tiger Brokers / Bulletin Express, FilingReader, TipRanks, minichart.com.sg (secondary news summaries)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedAge (AR 2025)Background / educationSource

Dr. Shui On LEUNG (梁瑞安)

Executive Director, Chairman, CEO (also CSO function); Chair of Nomination Committee; Remuneration Committee member

Board Apr 2001; CEO Jan 2003

66

Founder. Immunomedics (1991–2000, executive director of biology research); MD, HK Institute of Biotechnology (2000–03); HKEX Biotech Advisory Panel; director of HK Genome Institute; adjunct professor HKUST. BSc/MPhil biochemistry and EMBA (CUHK); DPhil molecular biology (Oxford, 1989); Yale postdoc

AR 2025

Ms. Fang LIANG (梁芳)

Executive Director (from 3 Jul 2026); COO (from Mar 2026)

202645

Ex-ED and Chief Strategy Officer, Shanghai Argo Biopharmaceutical (2023–25); SVP Loyal Valley Capital; VP GP Healthcare Capital; Novartis NIBR scientist (2008–17). MBA Manchester; BSc Chemistry Lanzhou

AR 2025; Bulletin Express 27 Jul 2026

Ms. Xiaosu WANG (王小素)

Non-executive Director

19 Dec 2024

45

Securities affairs representative and board-office director, Hainan Haiyao (substantial shareholder)

AR 2025

Dr. Jianmin ZHANG (張健民)

Non-executive Director

6 Sep 2023

48

CSO and head of innovative medicine institute, Hainan Haiyao; ex-ApoPharma. PhD Chemistry (Alberta)

AR 2025

Ms. Lei XUE

Non-executive Director (no director's fee)

12 Jun 2026

——

AGM poll results, 12 Jun 2026

Mr. George William Hunter CAUTHERLEY

INED; Audit Committee

23 Dec 2019

83

55+ years in medical/pharma distribution in HK, China and SE Asia; Hon DBA Edinburgh Napier; OBE

AR 2025

Mr. Ping Cho Terence HON (韓炳祖)

INED; Chair of Audit Committee

31 Oct 2019

66

35+ years in finance; INED of Xiabuxiabu, 361 Degrees, Daphne; ex-CFO DTXS, China Dongxiang, TOM Group finance director. FCCA, HKICPA

AR 2025

Dr. Chi Ming LEE (李志明)

INED; Chair of Remuneration Committee

15 Jun 2021

72

Ex-AstraZeneca executive director, Translational Science (CNS/Pain); Bayer; Abbott; CUHK. PhD Cambridge

AR 2025

Ms. Chi Sau Giselle LEE (李之秀)

INED; Audit and Nomination Committees

30 Jun 2025

54

Ex-MD and Head of Asia, Barings AM; Man Group; Deutsche AM. MSc LSE

AR 2025

Mr. Nan SHEN (申楠)

INED; Audit and Nomination Committees

30 Jun 2025

44

MD, Sedgwick Yard (VC); ex-Goldman Sachs and UBS IBD. BA/MA Economics Cambridge; MSc Oxford

AR 2025

“—” = not publicly disclosed.

Board of Directors — Dr. Shui On Leung

NameTitleSinceBackgroundSource

Dr. Shui On Leung

Chairman, CEO, CSO function

2001/2003

See above

AR 2025

Ms. Fang Liang

COO, Executive Director

Mar 2026

See above

AR 2025

Mr. Jianping HUA (華劍平), 44

CFO; authorised representative

Jan 2019

Ex-vice CFO Fosun Pharma; ex-CFO and ED of Sisram Medical; PwC Zhong Tian

AR 2025

Dr. Ka Wa Benny CHEUNG, 46

Director (Quality Control); IP matters

Joined 2010

PhD Immunology (HKU)

AR 2025

Mr. Guolin XU, 42

Director (Clinical and Regulatory Affairs)

Joined 2009

MPhil CUHK

AR 2025

Mr. Yuande ZHANG, 45

Director (Marketing)

Feb 2023

Ex-Chia Tai-Tianqing, Qilu

AR 2025

Board & Management Changes

DateChangeContext

29 May 2025

INED Dylan Carlo Tinker passed away

—

6–9 Jun 2025

Shanchun Wang ceased as President (China) and resigned as ED

Precedes RA BLA withdrawal; China commercial build-out wound down

30 Jun 2025

Giselle Lee and Nan Shen appointed INEDs

Restores INED count

8 Oct 2025

Company secretary Ivy Chow replaced by Florence Lai (PwC)

Outsourced secretarial function

Mar 2026

Fang Liang appointed COO

Brings BD, financing and investor credentials for the out-licensing strategy

31 Mar 2026

NED Haigang Chen resigned

Pre-IPO investor representative exits

1 Apr 2026

NED Xun Dong (Yunnan Baiyao) resigned

Cornerstone-linked director exits

12 Jun 2026

Lei Xue appointed NED

—

3 Jul 2026

Fang Liang appointed ED

Second executive on board

Major Shareholders

HolderShares% of issuedDate of recordSource

Hainan Haiyao Co., Ltd. (SZSE: 000566)

158,882,11511.46

29 Aug 2025

etnet; HKEX completion announcements. Shares charged to China CITIC Bank (security interest)

Dr. Shui On Leung (CEO/Chairman)

129,729,2009.36

29 Aug 2025

etnet

Mr. Jing Qiang (former President; via Grogene and others)

123,123,0708.88

16 Oct 2025

etnet

Apricot Capital

117,922,6898.66

15 Aug 2025

etnet

Ms. Xu Sijia

89,802,1056.59

15 Aug 2025

etnet

Other shareholders (residual)

~767.1 m

~55.0

Derived

—

Competitive Landscape

Competitor Detail

SinoMab asset / indicationCompetitor (company)MechanismStage / statusRelative positioning

SM17 – AD

Dupilumab (Sanofi/Regeneron)

IL-4Rα

Marketed global standard of care

Incumbent; SinoMab claims faster itch relief (cross-trial)

SM17 – AD

Lebrikizumab (Eli Lilly / Almirall)

IL-13

Marketed

Type-2 competitor

SM17 – AD

Tralokinumab (LEO Pharma)

IL-13

Marketed

Type-2 competitor

SM17 – AD

Nemolizumab (Galderma)

IL-31RA

Marketed (itch-focused)

Direct competitor on pruritus

SM17 – AD

Upadacitinib (AbbVie); abrocitinib (Pfizer)

JAK1

Marketed

High efficacy, boxed safety warnings; SinoMab positions on safety

SM17 – AD

Rocatinlimab (Amgen/Kyowa Kirin); amlitelimab (Sanofi)

OX40 / OX40L

Late-stage

Next-generation disease modifiers

SM17 – AD (China)

Stapokibart / CM310 (Keymed Biosciences); other Chinese IL-4Rα biosimilars and novel agents (e.g., Akeso, Hengrui)

IL-4Rα

Marketed or late-stage in China

Price pressure in China market

SM17 – asthma / CRSwNP

Tezepelumab (Amgen/AstraZeneca); itepekimab (Sanofi/Regeneron)

TSLP / IL-33 alarmins

Marketed / late-stage

Direct alarmin-class competitors; IL-25 is the least-advanced alarmin

SM17 – IBD

Vedolizumab (Takeda); ustekinumab (J&J); risankizumab (AbbVie); mirikizumab (Lilly); anti-TL1A (Merck, Roche, Sanofi)

Integrin / IL-23 / TL1A

Marketed / late-stage

Crowded; SinoMab differentiates on anti-fibrosis (preclinical)

Suciraslimab – SLE

Belimumab (GSK); anifrolumab (AstraZeneca); telitacicept (RemeGen, China); obinutuzumab (Roche, LN); CD19 CAR-T and T-cell engagers

BLyS / IFNAR / TACI / CD20 / CD19

Marketed / emerging

Non-depleting CD22 is novel but preclinical in SLE

hC2 – AA / vitiligo

Baricitinib (Lilly); ritlecitinib (Pfizer); deuruxolitinib (Sun Pharma); ruxolitinib cream (Incyte); IL-15/CD122 biologics in development

JAK / γc-pathway

Marketed / clinical

Biologic "upstream of JAK" angle

bsAb – osteoporosis

Denosumab (Amgen and biosimilars); romosozumab (Amgen/UCB); teriparatide/abaloparatide

RANKL / sclerostin / PTH

Marketed

First-in-class bispecific concept; preclinical

Competitor Detail (Annual)

MetricSinoMab (FY2025)

Revenue

RMB0

Net margin

NM (loss RMB105.0 m)

R&D intensity

NM; R&D RMB81.6 m

AD asset stage

Phase 2 (China)

Company Snapshot

42

Employees

2001

Founded

New Territories, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • First-in-class lead asset with strong early signal. SM17 Phase 1b high dose: NRS-4 91.7%, EASI-75 75%, IGA 0/1 41.7% (AR 2025, 7 Apr 2025 data).
  • Formulation de-risked. SC bridging study in 30 subjects showed no ≥Grade 3 drug-related TEAE or SAE (Interim 2026).
  • Fast Phase 2 enrolment. 86 of ~210 patients enrolled within three months of first dosing, described as "ahead of schedule" (Interim 2026).
  • Validated deal-making. SN1011 progressed to a US$112.5 m upfront and US$1.03 bn milestone sublicence to Travere, with SinoMab entitled to percentage shares (Interim 2026).
  • Expanding IP estate. Patents (granted plus pending) rose from 93 to 124 between Dec 2025 and Jun 2026; multi-jurisdiction grants on SM03 and SM09 (Interim 2026).
  • Leaner cost base. FY2025 net loss fell 43.3% to RMB105.0 m; admin costs down RMB21.3 m (AR 2025).

Weaknesses

  • No revenue after 25 years and seven years listed. Cumulative FY2021–25 losses of RMB1,105.6 m (derived from AR 2025).
  • Flagship failure. Suciraslimab RA BLA withdrawn July 2025 after CDE communications, despite a Phase 3 primary endpoint met in 2023 (AR 2025).
  • Liquidity thin and burn re-accelerating. Funding fell from RMB351.5 m to RMB196.5 m in six months; borrowings RMB260.2 m, of which RMB114.4 m is due within one year (Interim 2026).
  • Value destruction on fixed assets. RMB56.3 m impairment on the Suzhou campus sold at RMB280 m vs NBV RMB336.3 m (Interim 2026).
  • Governance concentration. Combined Chair/CEO (CG Code C.2.1 deviation); founder also leads science. Board self-assesses science adequacy at 40% and governance/risk at 20% (AR 2025 skills matrix).
  • Small team. 95 employees and 42 R&D staff (AR 2025; Interim 2026).

Opportunities

  • SM17 Phase 2 readout (1Q 2027 guidance) could support a global licence. China outbound licensing reached ~US$110 bn in 1H 2026 (Interim 2026).
  • IBD expansion. IND approved Feb 2026; Phase 1 can be skipped (Interim 2026).
  • hC2 dual FDA/NMPA IND in 4Q 2026 for alopecia areata, a market with JAK-safety limitations (Interim 2026).
  • SN1011 milestones and royalties flowing via Everest and Travere across up to five indications (Interim 2026).
  • Osteoporosis bsAb benefits from FDA's December 2025 BMD-endpoint acceptance (Interim 2026).
  • Non-dilutive cash from the Suzhou sale of RMB280 m against total funding of RMB196.5 m (Interim 2026).

Threats

  • AD crowding by IL-4Rα, IL-13, IL-31, OX40 and JAK agents, plus Chinese domestic entrants.
  • Alarmin class leadership held by TSLP (tezepelumab) and IL-33 (itepekimab) programmes with large sponsors.
  • Regulatory risk in China. CDE required more efficacy evidence for Suciraslimab, prompting the 2025 withdrawal (Tiger Brokers / AR 2025).
  • Further dilution likely. 20% general issuance mandate renewed June 2026; shares rose 27% in 2025 (AGM results; derived).
  • Pledged major holding. Hainan Haiyao's 11.46% stake is charged to China CITIC Bank (HKEX completion announcements).
  • Execution friction on disposal. Circular delayed twice; completion depends on EGM approval and buyer performance, with MediLink as guarantor (HKEX 27 Jul and 10 Aug 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
31 Mar 2025FY2024 results: loss RMB185.1 m (−23.8%); change in use of proceeds HKEX annual results 2024Cost-down trajectory confirmed
7 Apr 2025SM17 Phase 1b AD positive topline AR 2025Re-rates SM17 as lead asset
13 May 2025Placing of 112.8 m shares at HK$1.10 agreed (closed 29 May) AR 2025Emergency liquidity at trough valuation
29 May 2025INED Dylan Tinker dies AR 2025Board vacancy
Jun 2025Everest presents positive EVER001 (SN1011) PMN Phase 1b/2a data at ERA 2025 AR 2025Validates out-licensed asset
6–9 Jun 2025President (China) Shanchun Wang departs AR 2025Signals end of RA commercial plan
30 Jun 2025AGM; INEDs Giselle Lee and Nan Shen appointed AR 2025; TipRanksGovernance refresh
Jul 2025Suciraslimab preclinical SLE "breakthrough" results announced AR 2025Narrative support for pivot
14 Jul 2025RA BLA voluntarily withdrawn; shares rose ~17–18% intraday to HK$2.42 AR 2025; Tiger BrokersEnds flagship's near-term approval path; market rewarded the pivot
22 Jul 2025Placing of 182.1 m shares at HK$2.03 agreed (~13% dilution) AR 2025; TipRanksMajor recapitalisation
12 Aug 2025SYSU-IAS three-year cooperation AR 2025R&D capacity without capex
15/29 Aug 2025July placing completed (HK$369.5 m net) AR 2025Balance sheet repaired
29 Aug 20251H 2025 results: loss RMB49.8 m (vs RMB90.6 m); stock rose ~18% to HK$2.70 in early Sep FilingReader; Tiger BrokersCost discipline
8 Oct 2025Company secretary changed to PwC's Florence Lai AR 2025Administrative
Oct 2025SM17 SC bridging study first cohort dosed AR 2025Enables SC Phase 2
11 Dec 2025SM17 IBD IND accepted by CDE AR 2025Indication expansion
Jan 2026Management at 44th J.P. Morgan Healthcare Conference Interim 2026BD outreach
24 Feb 2026SM17 IBD IND approved by NMPA; stock up ~4.5% to HK$2.10 Interim 2026; Tiger BrokersSecond SM17 indication cleared
12 Mar 2026Haikou lease termination (connected transaction with Haiyao subsidiary) HKEX 12 Mar 2026Asset-light pivot
23–24 Mar 2026FY2025 results: loss RMB105.0 m (−43.3%); revised use of proceeds ACN Newswire 24 Mar 2026; AR 2025Best result since IPO
25 Mar 2026SM17 SC bridging favourable topline Interim 2026De-risks Phase 2 formulation
Mar 2026Fang Liang appointed COO AR 2025BD-oriented hire
31 Mar–1 Apr 2026First patient dosed in SM17 Phase 2 AD; NEDs Chen and Dong resign Interim 2026; AR 2025Lead asset enters mid-stage; investor directors exit
7 Apr 2026Remaining global SN1011 rights licensed to Everest Interim 2026Consolidates BTK monetisation
27 Apr 2026Annual Report 2025 published; AGM circular (10% buyback and 20% issue mandates) HKEX; Tiger BrokersRoutine
May 2026hC2 data at SID 2026; Dr. Leung at LifeArc Translational Science Summit (UK) Interim 2026; ACN Newswire 13 May 2026Pipeline visibility
2 Jun 2026Everest–Travere SN1011 licence (US$112.5 m upfront, up to US$1.03 bn milestones) Interim 2026External validation; possible cash to SinoMab
Jun 2026BIO 2026 attendance; SM03 paper in *J. Transl. Autoimmun.*; hC2 paper in *JID* Interim 2026Visibility
~10–11 Jun 2026Stock rose ~26% to HK$1.36 in late trading on pipeline and BD speculation Tiger BrokersSentiment volatility
12 Jun 2026AGM: all resolutions passed at 100%; Lei Xue appointed NED; EY re-appointed Bulletin ExpressGovernance
3 Jul 2026Fang Liang appointed Executive Director financialfilings.comManagement depth
6 Jul 2026Suzhou disposal SPA (RMB280 m; RMB56.3 m impairment) Interim 2026Liquidity versus value-destruction trade-off
24 Jul 202618.03 m options granted to one director and one employee Interim 2026Incentive alignment; dilution
27 Jul & 10 Aug 2026Two delays to the disposal circular (to 10 Aug, then 21 Aug) HKEXExecution friction
31 Aug 20261H 2026 results: loss RMB127.4 m (RMB71.1 m ex-impairment); funding RMB196.5 m; 86 of ~210 Phase 2 patients enrolled Interim 2026Burn re-accelerating with Phase 2
7 Sep 2026Scheduled EGM to approve Suzhou disposal Interim 2026–

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment: Segment loss before tax rose from CNY -243.1 Mn in FY2023 to CNY -105 Mn in FY2025.
SinoMab BioScience Limited — Revenue by Segment
Series (CNY Mn)FY2023FY2024FY2025
Segment loss before tax-243.1-185.1-105
Segment R&D costs135.494.881.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.